Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Zentalis (ZNTL) Q2 Loss Narrows 70%

TheMotleyFool 
0 0 07.08.25
Zentalis (ZNTL) Q2 Loss Narrows 70%
 

Zentalis Pharmaceuticals (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company focused on developing cancer therapies, released its second quarter earnings on August 6, 2025. The headline news was a much narrower net loss per share than forecast: it posted a GAAP EPS of $0.37 for Q2 2025, better than analyst projections of a $(0.59) loss. As in past periods, it reported no revenue. Zentalis extended its cash runway well into 2027. Overall, the period reflects tighter financial discipline and progress on restructuring, with investors waiting for critical clinical trial data.

Source: Analyst estimates for the quarter provided by FactSet.

Zentalis Pharmaceuticals is a biotechnology company developing targeted therapies for cancer. Its main product candidate is azenosertib, a WEE1 inhibitor designed to treat certain hard-to-treat cancers.

Continue reading


Source Fool.com

Electro Power Systems S.A. Stock

Show more
Like: 0
ZNTL
Share

Comments

Not a member yet? Sign up for free!